DRUG DEVELOPMENT PIPELINE

Back to the Drug Development Pipeline

GLPG2222

Phase Two

Phase Two

Therapeutic Approach

Restore CFTR Function

GLPG2222 is a new CFTR corrector, designed to fix and restore the function of the defective CFTR protein.

Status

A phase 2A study to test the safety and tolerability of GLPG2222 in people with CF who have two copies of the F508delCFTR mutation will begin soon.

Sponsor

This program is sponsored by Galapagos and is being conducted within the Cystic Fibrosis Foundation's Therapeutics Development Network.

Contact us about GLPG2222 >